Opus Genetics, Inc.

IRD Nasdaq SEC CIK 1228627
Follow Opus Genetics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.1M −63.1% vs same quarter last year
Net income −$46.5M −166.4% vs same quarter last year
EPS, diluted −$0.46 −84% vs same quarter last year
Operating cash flow −$14M −128% vs same quarter last year
Revenue by quarter
$4.3M
$4.4M
$2.9M
$3.1M
$3.9M
$2.2M
$755K
$1.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25M$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$14.2M−$49.6M
FY24$11M−$57.5M
FY23$19M−$10M
FY22$39.9M$17.9M
FY21$589K−$56.7M
FY20$0−$24.6M
FY19$3M−$6.2M
FY18-−$14.4M
FY17-−$25.3M
FY16-−$9.3M
FY15-−$14.4M
FY14-−$18.5M
FY13$0−$9.5M
FY12$0−$6.2M
FY11$0−$11.3M
MarginsShare of revenue
  • Operating margin
  • Net margin
−10000%−7500%−5000%−2500%0%2500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−271.9%−349.3%
FY24−564.7%−523.4%
FY23−55.5%−52.4%
FY2245.7%44.9%
FY21−3854.8%−9625.3%
FY20--
FY19−139.8%−205.6%
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
FY12--
FY11--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Opus Genetics
  • Healthcare median
−10000%−7500%−5000%−2500%0%2500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOpus GeneticsHealthcare median
FY25−349.3%−30.6%
FY24−523.4%−47%
FY23−52.4%−58%
FY2244.9%−80.4%
FY21−9625.3%−71.8%
FY20-−62.2%
FY19−205.6%−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%